Cipla settles patent litigation for cancer drug Revlimid with Celgene in US Updated : December 14, 2020 01:21 PM IST Revlimid, which is used to treat conditions such as multiple myeloma, is an approximately $8 billion brand in the US. Natco Pharma, Dr Reddy’s Laboratories and Alvogen have already settled on the drug. Like others, Cipla will sell a limited amount of volume of the drug until January 2026 after which there will be no volume caps.